CAR-T Therapy in China: Promising Progress, but Serious Risks Remain

More and more cancer patients are hearing about CAR-T therapy online. Some have read stories about patients achieving remission after treatment. Others have heard about China's rapid progress in this field and are considering traveling to China to receive CAR-T therapy.

There are good reasons for this growing interest.

CAR-T is a treatment that uses a patient's own immune cells, which are modified in a laboratory to recognize and attack cancer cells. It has already shown impressive results in certain blood cancers, including leukemia, lymphoma, and multiple myeloma.

China has also made significant progress. In June 2026, China approved the world's first CAR-T therapy for solid tumors. The treatment, known as Satri-cel, is designed for certain patients with advanced gastric cancer who meet specific medical criteria.

This is an important step forward, especially as solid tumors have traditionally been much harder to treat with CAR-T.

However, we believe patients should approach this treatment with realistic expectations.

CAR-T is not suitable for every type of cancer. Even when a patient qualifies, there is no guarantee that the treatment will work. Many CAR-T treatments are still being tested in clinical trials, and some carry serious risks.

A recent case in China is a reminder of why these risks should never be overlooked.

A Gastric Cancer Patient Died After Joining a CAR-T Clinical Trial in China

On September 4, 2026, there was a report about a 49-year-old gastric cancer patient who died after participating in a CAR-T clinical trial at Changhai Hospital in Shanghai.

According to the patient's wife, her husband was diagnosed with gastroesophageal junction adenocarcinoma in February 2025.

He underwent surgery to remove his entire stomach in March 2025, followed by six rounds of chemotherapy.

In September 2025, doctors found that the cancer had spread to lymph nodes behind the abdominal cavity. He continued receiving treatment, and his wife said his condition was generally stable afterward.

By December 2025, following second-line treatment at another hospital, his condition was assessed as basically stable.

His doctors had previously discussed CAR-T therapy with him. When his cancer returned, the possibility came up again.

According to his wife, the family was told that CAR-T could be a better treatment option. The patient's cancer also matched the target being studied.

They decided to join a Phase III clinical trial involving IMC002, an experimental CAR-T treatment developed by Chinese biotechnology company Immunofoco (易慕峰生物).

On January 14, 2026, the patient signed the trial's informed consent form.

He received three days of chemotherapy from February 25 to 27 to prepare his body for the CAR-T infusion.

On March 2, 2026, he received the experimental CAR-T cells.

Approximately seven hours after the infusion, he developed severe bleeding around both sides of his brain, along with brain herniation.

He underwent emergency brain surgery and was transferred to the intensive care unit in critical condition.

Sadly, he died on April 26, 2026.

The Family Questioned Whether the Treatment Was Responsible

The patient's wife told The Paper that the family had high hopes for the treatment.

She said they understood that CAR-T might not work, but they had not expected such a serious outcome.

One of her main concerns was whether the risks had been properly explained before her husband joined the trial.

According to her account, the informed consent document was 15 pages long. She said she did not see a clear warning about the possibility of death, and that the doctors had not explained every section in detail before they signed it.

She also recalled being told that complications such as cytokine release syndrome could occur, but could generally be managed.

After her husband's death, the family questioned whether the CAR-T infusion had contributed to the sudden brain bleeding.

However, the trial investigators reportedly did not consider the event to be related to the CAR-T product. According to the wife's account, they suggested that the complications may have been associated with the patient's underlying disease or chemotherapy.

The family disagreed with that assessment, particularly because the serious symptoms appeared so soon after the infusion.

The drug developer also disputed a causal link with the experimental treatment.

In a follow-up report on September 10, Immunofoco expressed condolences to the family. The company said the Phase III trial was continuing in accordance with Good Clinical Practice requirements and that relevant information would be disclosed as required by regulations.

An important point is that the publicly reported information does not establish that CAR-T directly caused this patient's death.

The cause of the complications and the question of responsibility remain disputed.

It is also important to distinguish IMC002, the experimental product involved in this case, from Satri-cel, the separately developed CAR-T treatment approved in China in June 2026.

Still, the case raises an important question for patients considering clinical trials: do they fully understand what could happen, including serious and potentially life-threatening complications?

Clinical trials are necessary for medical progress. But they exist precisely because researchers are still learning about a treatment's safety and effectiveness.

Novartis Also Paused CAR-T Trials After Three Patient Deaths

The case in China was not the only recent safety concern involving experimental CAR-T therapies.

In late August 2026, Swiss pharmaceutical company Novartis temporarily paused eight clinical trials involving its experimental CAR-T therapy, rapcabtagene autoleucel, also known as rap-cel.

According to Reuters and other international media reports, three patients died following a severe immune reaction known as immune effector cell-associated hemophagocytic syndrome (IEC-HS).

This complication can cause serious inflammation and damage to organs.

Unlike the gastric cancer trial in China, the affected Novartis trials were studying CAR-T for autoimmune and neurological conditions, including lupus and multiple sclerosis.

Novartis said it was reviewing the safety data and working with independent safety boards and regulators. Its separate oncology trials of rap-cel were not affected by the pause.

These are different treatments involving different medical conditions. The cases should not be treated as directly comparable.

Nevertheless, both reports remind us that CAR-T is a powerful form of treatment, and its effects on the immune system can sometimes be dangerous.

CAR-T Is Making Progress, but It Is Not a Miracle Cure

None of these events means that CAR-T is a failed treatment or that patients should avoid it altogether.

CAR-T has already changed the outlook for some patients with blood cancers. Research is also bringing new possibilities for patients with certain solid tumors.

China's progress in this field is encouraging, and further developments may offer more treatment options in the years ahead.

But it is important to remember that CAR-T is still developing, especially for many types of solid cancer.

A treatment that works well for one cancer may not work for another. Even two patients with the same cancer may respond very differently.

There are also significant differences between approved CAR-T treatments and experimental products being tested in clinical trials.

For patients who have already tried several treatments without success, it is understandable to look for something new. CAR-T may offer another opportunity, but its potential benefits must always be considered alongside its risks.

At China MedCare, we believe patients should have access to new medical developments, but also to clear and balanced information about what those treatments can realistically achieve.

Before considering CAR-T, patients should discuss their diagnosis, treatment history, eligibility, possible benefits, risks, and alternatives with an experienced specialist.

CAR-T is an exciting medical development, but it is not a magic injection that can cure every cancer.

We should remain hopeful about its future while being realistic about what it can offer patients today.